Biologics CDMO AsymBio to secure $184m from Asymchem Group, Hillhouse Qirui and other investors to support manufacturing growth
The funding, approximately 1.2397 billion yuan, will be used for AsymBio's principal business operations, further expansion of its manufacturing capacity, and scaling of client programs. Following the transaction, Asymchem Group's shareholding in its subsidiary AsymBio is set to rise to 83.4965%.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
Lombard (BARD) Token Analysis: Value, Investment Potential, and Risk Assessment
-
2
A Review of Major Global Digital Currency Trading Platforms and Market Landscape
-
3
Bitcoin Leveraged Trading Analysis: Definition, Operations, and Risk Management
-
4
A Rundown of Major Global Crypto Exchanges and Fee Comparison: How to Choose a Low-Cost Platform?
-
5
WSI Token: Role and Future Outlook of the WeSendit Decentralized File Sharing Platform
-
6
TATA Coin: Value and Long-Term Investment Considerations for a Community-Driven Token
-
7
SKL (SKALE): Ethereum Scaling, AI Agent Deployment, and Governance Dynamics Analysis
-
8
The Digital Currency Era: Fintech's Opportunities and Challenges Coexist
-
9
FLOKI Token Burn Mechanism Analysis and Price Outlook: Can it Reach $1?
-
10
Ethereum falls to a three-year low of $1,571, down approximately 68% from its all-time high.
Markets Today
Recommended Reading







